

COPY OF PAPER  
ORIGINALLY FILED

*Prolemt*  
*# 3/4*  
*ML*

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Morris Reichlin and Eugen Koren

Serial No.: 09/768,155

Art Unit: 1644

Filed: January 23, 2001

Examiner: Not Yet Assigned

RECEIVED  
MAR - 4 2002  
TECH CENTER 1600/2900

For: *METHOD FOR TREATMENT OF SLE*

Assistant Commissioner for Patents  
Washington, D.C. 20231

**Response to Notice to Comply With Requirements for Patent Applications  
Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures,  
Amendment and Declaration under 37 C.F.R. § 1.821 (f)**

Sir:

Pursuant to 37 C.F.R. 1.136(a), Applicants petition that the period for response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence disclosures mailed on June 8, 2001, in the above-identified application be extended for three months, up to and including November 8, 2001. A check for the fee of \$460.00 for a small entity under 37 C.F.R. §1.17(b) accompanies this petition. Also enclosed are amendments to the specification, a paper copy of the sequence listing and a clean copy of specification pages 6, 9, 21, 22, 25, 26, 27, and 28 amended to insert sequence ID numbers.

It is believed that no additional fee is required with this submission. However, should an

U.S.S.N.: 09/768,155  
Filed: January 23, 2001  
Response to Notice to Comply With Requirements for Patent Applications  
Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures,  
Amendment and Declaration under 37 C.F.R. § 1.821 (f)

additional fee be required, the Commissioner is hereby authorized to charge any additional fees to Deposit Account No. 50-1868.

Applicants note that the above-identified application contains nucleic acid and/or protein sequences as defined in 37 CFR § 1.821-1.825. The sequence listing for the instant application is identical to the sequence listing for application Serial No. 08/800,682, filed February 14, 1997.

In accordance with 37 CFR 1.821(e), please use the last filed computer readable form filed in application Serial No. 08/800,682 on March 3, 1998, as the computer readable form for the instant application. It is understood that the Patent and Trademark Office will make the necessary change in application number and filing date for the computer readable form that will be used for the instant application.

### **Amendment**

#### **In the Specification**

Please amend the specification as follows.

~~On~~ page 6, line 6, following "nucleotide" please insert --(SEQ ID NO:1)--.

~~On~~ page 6, line 7, following "acid" please insert --(SEQ ID NO:2)--.

~~On~~ page 6, line 13, following "proteins" please insert --(SEQ ID NOS:3 to 7)--.

~~On~~ page 6, line 14, following "regions" please insert --(SEQ ID NOS:8 to 12)--.

~~On~~ page 6, line 17, following "sequences" please insert --(SEQ ID NOS:3 to 7)--.

~~On~~ page 6, line 18, following "HSI" please insert --(SEQ ID NO:3)--.


U.S.S.N.: 09/768,155

Filed: January 23, 2001

Response to Notice to Comply With Requirements for Patent Applications  
Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures,  
Amendment and Declaration under 37 C.F.R. § 1.821 (f)

**Certificate of Mailing Under 37 C.F.R. § 1.8(a)**

I hereby certify that this paper, along with any paper referred to as being attached or enclosed, is being deposited with the United States Postal Service on the date shown below with sufficient postage as first-class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

  
Kimberly L. Adams

Date: November 7, 2001

09/768,155